All In Biotech

Drug Trial Radar · NCT01799993

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia

Last checked: Nov 19, 2026Latest source record: Jul 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 725 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

725

Actual

Start

Apr 13, 2013

Primary completion

Apr 7, 2017

Study completion Apr 7, 2017

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Nektar Therapeutics
First posted
Feb 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and more effective than placebo (aerosolized normal saline) administered as an aerosol by the PDDS Clinical every 12 hours, in intubated and mechanically-ventilated patients with Gram-negative Pneumonia. The secondary endpoint objectives are to evaluate the superiority of aerosolized BAY 41-6551 versus aerosolized placebo in pneumonia-related mortality, the Early Clinical Response at Day 10, the days on ventilation, and the days in the intensive care unit (ICU).

Conditions

  • Pneumonia, Bacterial

Interventions

  • Amikacin Inhalation Solution (BAY41-6551)Drug

    400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)

  • Aerosolized PlaceboDrug

    Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Surviving Through LFU VisitTime frame: Up to 28-32 days after start of study treatment

Locations

65 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Danbury, Connecticut

  • Site not named

    Hartford, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Hollywood, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Springfield, Illinois

  • Site not named

    Muncie, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Hazard, Kentucky

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Springfield, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Butte, Montana

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Brooklyn, New York

  • Site not named

    Mineola, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Youngstown, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Charleston, South Carolina

  • Site not named

    Wollongong, Australia

  • Site not named

    Blacktown, New South Wales, Australia

  • Site not named

    Clayton, Victoria, Australia

  • Site not named

    Belo Horizonte, Minas Gerais, Brazil

  • Site not named

    Campinas, São Paulo, Brazil

  • Site not named

    São José do Rio Preto, São Paulo, Brazil

  • Site not named

    Québec, Canada

  • Site not named

    Kingston, Ontario, Canada

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.